Roth Capital initiated coverage on BioHarvest Sciences with a new price target
$BHST
Roth Capital initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $10.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/19/2026 | $10.00 | Buy | Roth Capital |
| 5/5/2025 | $15.00 | Buy | Craig Hallum |
| 12/18/2024 | $12.00 | Buy | Maxim Group |
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on business operations.Fourth Quarter and Full Year 2025 Earnings CallDate: Tuesday, March 31, 2026Time: 4:30 PM Eastern TimeWebcast link: https://events.q4inc.com/attendee/512060117The Earnin
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately.Mr. Tsur has served on BioHarvest's Board since 2021 and has contributed meaningfully to the Company's strategic development and governance during a period of operational expansion, capital formation, product commercialization, and market positioning.Zaki Rakib, Chair
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 38th Annual Roth Conference taking place on March 22-24, 2026.CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event. 38th Annual Roth Conference for Growth CompaniesDate: March 22-24, 2026Location: The Ritz-Carlton Laguna Niguel- Dana Point, CAFormat: 1x1 MeetingsSobel said: "I am pleased to announce our invitation to the 38th Annual Ro
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
Roth Capital initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $10.00
Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00
Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on business operations.Fourth Quarter and Full Year 2025 Earnings CallDate: Tuesday, March 31, 2026Time: 4:30 PM Eastern TimeWebcast link: https://events.q4inc.com/attendee/512060117The Earnin
Strong VINIA Momentum and New CDMO Win Delivers 39% Year-Over-Year GrowthCompany Fortifies Balance Sheet with Recent $19.9 Million Instiutional Equity Raise Following $14.7 Million Strengthening of Balance Sheet via Accelerated Warrant Exercises and Debt-to-Equity Conversions in SeptemberVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2025.Third Quarter 2025 Operational HighlightsAll figu
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, November 13, 2025 to discuss the Company's third quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate,
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately.Mr. Tsur has served on BioHarvest's Board since 2021 and has contributed meaningfully to the Company's strategic development and governance during a period of operational expansion, capital formation, product commercialization, and market positioning.Zaki Rakib, Chair
Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division